Volume 83, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Miltefosine is an oral agent used for cutaneous leishmaniasis treatment. An open-label, randomized, phase III clinical trial was carried out in the Colombian army population. Miltefosine, 50 mg capsule was taken orally three times per day for 28 days ( = 145) or meglumine antimoniate, 20 mg/kg body weight per day for 20 days by intramuscular injection ( = 143). The efficacy of miltefosine by protocol was 69.8% (85/122 patients) and 58.6% (85/145 patients) by intention to treat. For meglumine antimoniate, the efficacy by protocol was 85.1% (103/121 patients) and 72% (103/143 patients) by intention to treat. No association was found between drug efficacy and or () species of responsible for infection. Adverse gastrointestinal events were associated with the use of miltefosine, the meglumine antimoniate treatment was associated with adverse effects on the skeletal musculature, fever, cephalea, and higher toxicity in kidney, liver, pancreas, and hematological system.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Neuber H, , 2008. Leishmaniasis. J Dtsch Dermatol Ges 6: 754765.[Crossref] [Google Scholar]
  2. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, , 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev CD004834. [Google Scholar]
  3. Alvar J, Yactayo S, Bern C, , 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552557.[Crossref] [Google Scholar]
  4. Bailey MS, Lockwood DN, , 2007. Cutaneous leishmaniasis. Clin Dermatol 25: 203211.[Crossref] [Google Scholar]
  5. Soto J, Soto P, , 2006. Current situation and future of antileishmanial therapy in Colombia. Biomedica (Bogota) 26 (Suppl 1): 194206. [Google Scholar]
  6. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K, , 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599614.[Crossref] [Google Scholar]
  7. Murray HW, Berman JD, Davies CR, Saravia NG, , 2005. Advances in leishmaniasis. Lancet 366: 15611577.[Crossref] [Google Scholar]
  8. Ouellette M, Drummelsmith J, Papadopoulou B, , 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7: 257266.[Crossref] [Google Scholar]
  9. Palumbo E, , 2009. Current treatment for cutaneous leishmaniasis: a review. Am J Ther 16: 178182.[Crossref] [Google Scholar]
  10. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, Pollack H, , 2007. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44: 15491554.[Crossref] [Google Scholar]
  11. Berman JD, , 1996. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 14: 519522.[Crossref] [Google Scholar]
  12. Sampaio RN, de Paula CD, Sampaio JH, Furtado Rde S, Leal PP, Rosa TT, Rodrigues ME, Veiga JP, , 1997. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop 30: 457463.[Crossref] [Google Scholar]
  13. Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, Almeida RP, , 2004. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190: 17931796.[Crossref] [Google Scholar]
  14. Seaton RA, Morrison J, Man I, Watson J, Nathwani D, , 1999. Out-patient parenteral antimicrobial therapy—a viable option for the management of cutaneous leishmaniasis. QJM 92: 659667.[Crossref] [Google Scholar]
  15. Osorio LE, Palacios R, Chica ME, Ochoa MT, , 1998. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 351: 498499.[Crossref] [Google Scholar]
  16. Momeni AZ, Aminjavaheri M, Omidghaemi MR, , 2003. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat 14: 2629.[Crossref] [Google Scholar]
  17. Singh S, Singh R, Sundar S, , 1995. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol 34: 120121.[Crossref] [Google Scholar]
  18. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID, , 1998. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg 59: 889892. [Google Scholar]
  19. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, , 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232236.[Crossref] [Google Scholar]
  20. Bari AU, Rahman SB, , 2003. A therapeutic update on cutaneous leishmaniasis. J Coll Physicians Surg Pak 13: 471476. [Google Scholar]
  21. Croft SL, Engel J, , 2006. Miltefosine–discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100 (Suppl 1): S4S8.[Crossref] [Google Scholar]
  22. Croft SL, Snowdon D, Yardley V, , 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei . J Antimicrob Chemother 38: 10411047.[Crossref] [Google Scholar]
  23. Escobar P, Matu S, Marques C, Croft SL, , 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81: 151157.[Crossref] [Google Scholar]
  24. Nakayama H, Loiseau PM, Bories C, Torres de Ortiz S, Schinini A, Serna E, Rojas de Arias A, Fakhfakh MA, Franck X, Figadere B, Hocquemiller R, Fournet A, , 2005. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 49: 49504956.[Crossref] [Google Scholar]
  25. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, , 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272275. [Google Scholar]
  26. Escobar P, Yardley V, Croft SL, , 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45: 18721875.[Crossref] [Google Scholar]
  27. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, , 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 17391746.[Crossref] [Google Scholar]
  28. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW, , 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352: 18211823.[Crossref] [Google Scholar]
  29. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, , 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 12661272.[Crossref] [Google Scholar]
  30. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, , 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: E57E61.[Crossref] [Google Scholar]
  31. Velez ID, , 1996. Diagnóstico. Antioquia Ud, ed. Leishmaniosis Manual de Procedimientos para el Diagnóstico de la Leishmaniosis Cutánea Americana Medellín Colombia: University of Antioquia, 1318. [Google Scholar]
  32. Singh S, Dey A, Sivakumar R, , 2005. Applications of molecular methods for Leishmania control. Expert Rev Mol Diagn 5: 251265.[Crossref] [Google Scholar]
  33. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P, , 2003. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176181.[Crossref] [Google Scholar]
  34. Velez ID, Hendrickx E, Robledo SM, del Pilar Agudelo S, , 2001. Gender and cutaneous leishmaniasis in Colombia. Cad Saude Publica 17: 171180.[Crossref] [Google Scholar]
  35. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, , 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210211. [Google Scholar]
  36. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, , 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350356.[Crossref] [Google Scholar]
  37. Gonzalez LM, Velez ID, , 2006. Miltefosine for disseminated cutaneous leishmaniasis. Biomedica (Bogota) 26 (Suppl 1): 1316. [Google Scholar]

Data & Media loading...

  • Received : 28 Jan 2010
  • Accepted : 21 Apr 2010
  • Published online : 05 Aug 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error